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Replication-selective tumor-speciﬁc viruses constitute a novel approach for treatment of neoplastic 
disease.  These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral 
propagation within the tumor.  Human telomerase is highly active in more than 85ｵ of primary can-
cers,  regardless of their tissue origins,  and its activity correlates closely with human telomerase 
reverse transcriptase (hTERT) expression.  We constructed an attenuated adenovirus 5 vector 
(Telomelysin,  OBP-301),  in which the hTERT promoter element drives expression of E1 genes.  Since 
only tumor cells that express telomerase activity would activate this promoter,  the hTERT proximal 
promoter would allow for preferential expression of viral genes in tumor cells,  leading to selective 
viral replication and oncolytic cell death.  Lymphatic invasion is a major route for cancer cell dissemi-
nation,  and adequate treatment of locoregional lymph nodes is required for curative treatment in 
patients with gastrointestinal tumors.  We demonstrated that intratumoral injection of Telomelysin 
mediates eﬀective in vivo purging of metastatic tumor cells from regional lymph nodes.  Moreover,  
using noninvasive whole-body imaging,  we found that intratumoral injection of Telomelysin followed 
by regional irradiation induces a substantial antitumor eﬀect,  resulting from tumor cell-speciﬁc radio-
sensitization,  in an orthotopic human esophageal cancer xenograft model.  These results illustrate the 
potential of oncolytic virotherapy as a promising strategy in the management of human gastrointesti-
nal cancer.
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iruses are the simplest form of life carrying 
genetic materials and are capable of entering 
host cells eﬃciently.  Because of these properties,  
many viruses have been adapted as gene transfer vec-
tors [1-3],  for which purpose adenoviruses have been 
well studied and characterized.  Adenoviruses are 
large,  double-stranded DNA viruses with tropism for 
many human tissues such as bronchial epithelia,  hepa-
tocytes,  and neurons.  Furthermore,  they are capable 
of transducing nonreplicating cells and can be grown 
to high titers in vitro,  a feature beneﬁcial for clinical 
use.  High titers of replication-defective adenoviruses 
can be produced and have been successfully used in 
eukaryotic gene expression [1,  4,  5].  Numerous 
studies using in vitro and animal models have tested a 
wide variety of adenoviral gene therapy agents and 
reported potential beneﬁcial eﬀects for diﬀerent tar-
get diseases,  including their tolerability and safety 
[6-9].
　 Oncolytic viruses that can selectively replicate in 
tumor cells and lyse infected cells have been exten-
sively investigated as novel anticancer agents [3,  10,  
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11].  These vectors are designed to induce virus-
mediated lysis of tumor cells after selective viral 
propagation within the tumor cell while remaining 
innocuous to normal tissues [12].  Onyx-015 is one 
such adenovirus with the E1B 55-kDa gene deleted,  
engineered to selectively replicate in and lyse p53-
deﬁcient cancer cells; clinical trials of intratumoral 
injection of Onyx-015 [13] alone or in combination 
with cisplatin/5-ﬂuorouracil have been conducted in 
patients with recurrent head and neck cancer [14,  
15].  However,  a subsequent study clariﬁed that the 
capacity of Onyx-015 to replicate independently of the 
cell cycle does not correlate with the status of p53 
[16] but is determined by the late viral RNA export 
[17].
　 The optimal treatment of human cancer requires 
improvement of the therapeutic ratio,  maximizing the 
cytotoxic eﬃcacy of an agent on tumor cells while 
minimizing its eﬀect on normal cells.  This may not be 
an easy task because the majority of normal cells sur-
rounding tumors are sensitive to cytotoxic agents.  
Thus,  to establish reliable therapeutic strategies for 
human cancer,  it is important to seek genetic or epi-
genetic targets present only in cancer cells.  One tar-
geting strategy has involved the use of tissue-speciﬁc 
promoters to restrict gene expression or viral replica-
tion in speciﬁc tissues.  A large number of diﬀerent 
tissue-speciﬁc promoters have been used for viro-
therapy applications; however,  tumor-speciﬁc rather 
than tissue-speciﬁc promoters would be more advanta-
geous targets.  For example,  the promoter of human 
telomerase reverse transcriptase (hTERT) is highly 
active in most tumor cells but inactive in normal 
somatic cell types.
　 This review highlights some very promising 
advances in cancer therapeutic technologies using the 
hTERT promoter against human gastrointestinal can-
cer.
Telomerase Activity for Transcriptional 
Cancer Targeting
　 One of the hallmarks of cancer is unregulated 
proliferation of a certain cell population,  which even-
tually aﬀects normal cellular function in the human 
body.  This process almost universally correlates with 
the activation of telomerase.  Tumor cells can maintain 
telomere length predominantly due to telomerase,  and 
its activity is detected in about 85ｵ of malignant 
tumors [18],  whereas telomerase is absent in most 
normal somatic tissues [19],  with a few exceptions 
including peripheral blood leukocytes and certain stem 
cell populations [20,  21].  The strong association 
between telomerase activity and malignant tissue 
makes telomerase a plausible target for the diagnosis 
and treatment of cancer [22].
　 The enzyme telomerase is a ribonucleoprotein 
complex responsible for the addition of TTAGGG 
repeats to the telomeric ends of chromosomes,  and 
contains three components: the RNA subunit (known 
as hTR,  hTER,  or hTERC) [23],  the telomerase-
associated protein (hTEP1) [24],  and the catalytic 
subunit (hTERT) [25,  26].  Both hTR and hTERT 
are required for the reconstitution of telomerase 
activity in vitro [27] and,  therefore,  represent the 
minimal catalytic core of telomerase in humans [28].  
Both hTR and hTERT transcripts are easily detect-
able in cancer cells but are either absent or at low 
levels in normal cells [29]; however,  the hTR pro-
moter is always stronger than hTERT with presum-
ably more background [30].  Thus,  the hTERT pro-
moter region can be substantially used as a ﬁne-tuning 
molecular switch that works exclusively in tumor cells 
(Fig.  1).
hTERT Promoter-driven Telomerase-speciﬁc 
Oncolytic Adenovirus
　 The use of modiﬁed adenoviruses that replicate and 
complete their lytic cycle preferentially in cancer cells 
is a promising strategy for the treatment of cancer.  
One approach to achieving tumor speciﬁcity of viral 
replication is based on the transcriptional control of 
genes that are critical for virus replication such as 
E1A or E4.  As described above,  telomerase,  espe-
cially its catalytic subunit hTERT,  is expressed in the 
majority of human cancers,  and the hTERT promoter 
is preferentially activated in human cancer cells [18].  
Thus,  the broadly applicable hTERT promoter might 
be a suitable regulator of adenoviral replication.  
Indeed,  it has been reported previously that the tran-
scriptional control of E1A expression via the hTERT 
promoter could restrict adenoviral replication to 
telomerase-positive tumor cells and eﬃciently lyse 
tumor cells [31-36].  Furthermore,  Kuppuswamy et al.  
have recently developed a novel oncolytic adenovirus 
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(VRX-011),  in which the replication of the vector 
targets cancer cells by replacing an adenovirus E4 
promoter with the hTERT promoter [37].  VRX-011 
could also overexpress the adenovirus death protein 
(ADP) (also known as E3-11.6K),  which is required 
for eﬃcient cell lysis and release of virions from cells 
at late stages of infection.
　 The adenovirus E1B gene is expressed early in 
viral infection and its gene product inhibits E1A-
induced p53-dependent apoptosis,  which in turn pro-
motes the cytoplasmic accumulation of late viral 
mRNA,  leading to a shut-down of host cell protein 
synthesis.  In most vectors that replicate under the 
transcriptional control of the E1A gene including 
hTERT-speciﬁc oncolytic adenoviruses,  the E1B gene 
is driven by the endogenous adenovirus E1B promoter.  
However,  Li et al.  [38] have demonstrated that tran-
scriptional control of both E1A and E1B genes by the 
α- fetoprotein (AFP) promoter with the use of IRES 
signiﬁcantly improved the speciﬁcity and the therapeu-
tic index in hepatocellular carcinoma cells.  Based on 
the above information,  we developed Telomelysin 
(OBP-301),  in which the tumor-speciﬁc hTERT pro-
moter regulates both the E1A and E1B genes (Fig.  2).  
Telomelysin is expected to control viral replication 
more stringently,  thereby providing better therapeu-
tic eﬀects in tumor cells as well as attenuated toxicity 
in normal tissues [39].
In Vitro and In Vivo Antitumor Eﬃcacy of 
Telomelysin in Human Gastrointestinal Cancer
　 As the majority of human cancer cells acquire 
immortality and unregulated proliferation by expres-
sion of hTERT [18],  hTERT-speciﬁc Telomelysin 
could theoretically possess a broad-spectrum antineo-
plastic activity against a variety of human tumors [39,  
40].  Telomelysin induced selective E1A and E1B 
expression in cancer cells,  which resulted in viral 
replication at 5-6 logs by 3 days after infection;  on 
the other hand,  Telomelysin replication was attenu-
ated up to 2 logs in cultured normal cells [39,  40].
　 In vitro cytotoxicity assays demonstrated that 
Telomelysin could eﬃciently kill various types of 
human gastrointestinal cancer cell lines including 
esophageal cancer,  gastric cancer,  and colorectal 
cancer in a dose-dependent manner [41].  These data 
clearly demonstrate that Telomelysin exhibits desir-
able features for use as an oncolytic therapeutic agent,  
as the proportion of cancers potentially treatable by 
Telomelysin is extremely high.
　 The in vivo antitumor eﬀect of Telomelysin was also 
investigated using athymic mice carrying xenografts,  
because most murine tumor cells are known to express 
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Fig. 1　 Scheme of the proximal promoter of hTERT.  Putative protein-binding sites for various transcription factors are indicated.
low levels of the coxsackievirus and adenovirus recep-
tor (CAR).  Intratumoral injection of Telomelysin into 
human colorectal tumor xenografts resulted in a sig-
niﬁcant inhibition of tumor growth and enhancement of 
survival [39,  40].  Macroscopically,  massive ulcer-
ation was noted on the tumor surface after injection of 
high-dose Telomelysin,  indicating that Telomelysin 
induced intratumoral necrosis due to direct lysis of 
tumor cells by virus replication in vivo [42].
Lymph Node Metastasis in Human 
Gastrointestinal Cancer
　 Lymph node status provides important information 
for both the diagnosis and treatment of human gastro-
intestinal cancer.  Lymphatic invasion is a major route 
for cancer cell dissemination,  and lymph node metas-
tasis represents aggressive tumor behavior and is 
associated with high rates of regional recurrence,  
which portends a poor outcome and may produce 
marked morbidity [43-45].  Therefore,  adequate 
resection of the locoregional lymph nodes is required 
for curative treatment in patients with gastrointestinal 
malignancies such as esophageal,  gastric,  and col-
orectal cancers [46,  47].  Extended lymphadenec-
tomy,  however,  may greatly impair quality of life,  
especially for patients with early-stage epithelial 
neoplasms in the gastrointestinal tract [48].  Their 
primary tumors can be removed by new endoluminal 
therapeutic techniques such as endoscopic submucosal 
dissection; however,  patients with submucosal inva-
sion,  lymphovascular inﬁltration of cancer cells,  or 
undiﬀerentiated histology often become candidates for 
surgical organ resection with lymphadenectomy,  
because there is a risk of regional lymph node metas-
tasis,  although the frequency is relatively low [49].  
For example,  resection of upper gastrointestinal 
organs such as gastrectomy and esophagectomy may 
result in body weight loss and microgastria.  A less 
invasive way to selectively treat lymph node metasta-
sis would beneﬁt these patients by allowing them to 
avoid prophylactic surgery.
In Vivo Lymphatic Spread of Virus on 
Regional Lymph Nodes
　 The therapeutic potential of viral agents against 
primary tumors as well as their systemic biodistribu-
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Fig. 2　 Structures of telomerase-speciﬁc oncolytic adenoviruses.  Telomelysin (OBP-301),  in which the hTERT promoter element drives 
the expression of E1A and E1B genes linked with an internal ribosome entry site.  TelomeScan (OBP-401) is a telomerase-speciﬁc replica-
tion-competent adenovirus variant,  in which the GFP gene is inserted under a cytomegalovirus promoter into the E3 region for monitoring 
viral replication.  Left panel,  schematic representation depicting major structural components of adenoviruses (hexon,  penton base,  and 
ﬁber).
tion targeting distant metastases has been intensively 
investigated [3,  10,  50].  Few studies,  however,  
have examined the ability of the virus to progress to 
the regional draining lymph nodes.  Recently,  Burton 
et al.  showed that replication-deﬁcient adenovirus 
could be successfully transported to the regional 
lymph nodes and non-invasively detect metastasis by 
expressing the prostate-speciﬁc reporter gene in an 
orthotopic prostate xenograft [51].
　 To verify that oncolytic adenoviruses progress 
through the lymphatic vessels to the regional lymph 
nodes,  we used an orthotopic mouse model of human 
rectal cancer with spontaneous lymph node metastasis.  
We have demonstrated that intratumoral injection of 
the telomerase-speciﬁc replication-selective GFP-
expressing adenovirus TelomeScan (OBP-401) (Fig.  
2) could eﬃciently visualize metastatic lymph nodes 
with GFP ﬂuorescence signals in human cancer xeno-
graft models [52,  53].  These studies suggest the 
possible application of the adenovirus vectors as a 
lymphotropic agent for the treatment of lymph node 
metastasis.
In Vitro Purging of Human Colorectal Cancer 
Cells by Telomelysin
　 In vitro purging experiments demonstrated that 
Telomelysin infection could selectively eliminate 
human tumor cells in the presence of human or mouse 
lymphocytes [54].  We used TelomeScan to visualize 
viable human tumor cells after purging with 
Telomelysin,  as we have previously shown the high 
sensitivity and speciﬁcity of this molecular imaging 
method [52,  53].  It has been reported that the ﬁber-
modiﬁed adenovirus serotype 5 (Ad5) and an adenovi-
rus vector based on another serotype such as 35 eﬃ-
ciently transduce exogenous genes into hematopoietic 
cells,  including stem cells; the unmodiﬁed Ad5,  how-
ever,  could rarely infect these cells because of the 
lack of CAR expression [55].  Indeed,  Ad5-based 
Telomelysin had no apparent eﬀects on the viability of 
lymphocytes in vitro.  These results suggest that nor-
mal lymphocytes in the regional lymph nodes could be 
strictly protected from Telomelysin-induced oncolysis 
because lymphocytes are not subject to Telomelysin 
infection and viral replication is also unlikely to occur 
in normal cells due to their low telomerase activity 
[20].
In Vivo Antitumor Eﬀect of Telomelysin on 
Lymph Node Metastasis
　 Mice bearing orthotopic human colorectal tumors 
received 3 rounds of intratumoral injection of 
Telomelysin at 2-day intervals beginning 2 weeks after 
the tumor inoculation.  Histopathological examination 
of the excised total lymph nodes showed that 
Telomelysin treatment considerably reduced the meta-
static rates.  We also used a simple real-time Alu PCR 
assay to quantify the few metastatic human tumor cells 
against a background of large numbers of mouse host 
cells [54].  This human-speciﬁc ampliﬁcation method 
enabled us to detect human tumor cells in a linear 
range of 103-108 cells/sample and to monitor the time-
dependent exponential growth of spontaneous lymph 
node metastasis from orthotopic colorectal tumor 
xenografts.  In accordance with the histologically 
conﬁrmed results,  the Alu PCR assay indicated that 
intratumoral injection of Telomelysin into the primary 
tumors signiﬁcantly inhibited lymph node metastasis 
with high levels of viral replication.
　 We also used TelomeScan and a three-dimensional 
optical detection system (IVIS 200) (Xenogeu,  Almeda,  
CA,  USA) to compare the extent of metastasis after 
Telomelysin and control treatments.  After 2 weeks of 
orthotopic implantation of human colorectal tumor 
cells,  Telomelysin was administered intratumorally 
for 5 cycles.  We then used the IVIS imaging system 
to explore the abdominal cavity at laparotomy follow-
ing a single injection of TelomeScan into tumors.  The 
number of GFP-positive lymph nodes and the GFP 
signal levels of individual lymph nodes were much 
higher in mock-treated control mice than in 
Telomelysin-treated mice.  Indeed,  the sum of GFP 
ﬂuorescence intensity in the abdominal cavity was 
signiﬁcantly lower in mice treated with Telomelysin,  
conﬁrming the in vivo biological purging eﬀect of 
Telomelysin.  The fact that two independent and highly 
sensitive approaches showed comparable results sug-
gests the potent in vivo purging eﬀect of oncolytic 
virotherapy on regional lymph nodes.
　 For eﬀective treatment of metastatic tumors,  
intravenously infused chemotherapeutic drugs must be 
distributed in suﬃcient concentrations into the tumor 
sites; by contrast,  oncolytic viruses can replicate in 
the tumor,  cause oncolysis,  and then release virus 
particles that could reach distant metastatic lesions.  
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Moreover,  intratumoral injection can avoid the hepa-
totoxicity that may be induced by systemic adenoviral 
administration.  Therefore,  low-dose intratumoral 
administration of oncolytic virus that causes the repli-
cation and release of newly formed viruses from tumor 
cells may be safer than traditional full-dose chemo-
therapy,  and certainly,  intratumoral administration of 
the virus allows for a safer dose than would its sys-
temic administration.
Preoperative Intratumoral Administration of 
Telomelysin against Lymph Node Metastasis
　 Currently,  surgery and radiation are the most 
eﬀective and clinically reliable local management 
strategies for human malignancies including lymphatic 
metastases.  Ionizing radiation targeting the lower half 
of the mouse body including primary tumors and the 
para-aortic lymphatic area did signiﬁcantly inhibit 
lymph node metastasis,  but systemic toxicity indicated 
by symptoms such as body weight loss was remarkable 
in irradiated mice compared to mice treated with 
Telomelysin.  In fact,  total body irradiation at a dose 
of 10Gy has been reported to be lethal in mice 
because of acute radiation syndromes involving the 
hematopoietic system and gastrointestinal tract [56].  
We demonstrated that regional injection of 
Telomelysin might be simpler and safer than radio-
therapy as a treatment for metastatic lymph nodes 
[54].
　 We also assessed the eﬀect of surgical resection of 
primary rectal tumors on lymph node metastasis.  
Unexpectedly,  metastatic tumor cells in the lymph 
nodes considerably increased after surgical removal of 
primary rectal tumors,  presumably due to the spread 
of tumor cells into the lymphatic circulation during the 
surgical procedure.  Another possible explanation of 
this phenomenon includes a decrease in angiogenic 
inhibitors such as angiostatin and endostatin secreted 
from the primary tumor mass [57].  In contrast,  
intratumoral injection of Telomelysin prior to surgical 
resection signiﬁcantly inhibited lymph node metasta-
sis.  Telomelysin causes viral spread into the regional 
lymphatic area and selectively replicates in neoplastic 
lesions,  resulting in eradication of lymph node metas-
tasis.  Tumor cells infected with Telomelysin in the 
primary tumors are also unable to metastasize to the 
regional lymph nodes.  Therefore,  although the surgi-
cal procedure itself has the potential to promote 
regional metastasis,  preoperative treatment with 
Telomelysin may prevent this undesirable event.
Ionizing Radiation and DNA Repair 
Machinery
　 Current treatment strategies for advanced cancer 
include surgical resection,  radiation,  and cytotoxic 
chemotherapy.  Preoperative or postoperative chemo-
radiation may improve local control and the survival of 
advanced cancer patients by minimizing the risk of 
dissemination during the surgical procedure,  increas-
ing the complete resection rate,  and eradicating 
microscopic residual tumor cells that are not surgi-
cally removed.  The lack of restricted selectivity for 
tumor cells is the primary limitation of radiotherapy,  
despite improved technologies such as stereotactic and 
hyperfractionated radiotherapy.  Although radiother-
apy is generally considered to be less invasive,  the 
maximum doses and treatment ﬁelds are limited to 
avoid cytotoxic eﬀects on the surrounding normal tis-
sues.  Therefore,  to improve the therapeutic index of 
radiotherapy,  there is a need for agents that eﬀec-
tively lower the threshold for radiation-induced tumor 
cell death while not compromising the tolerance of 
normal cells.  The safety and eﬃcacy of some candi-
dates are already being explored in clinical trials 
[58-60].
　 Ionizing radiation primarily targets DNA mole-
cules and induces double-strand breaks (DSBs) [61].  
Radiosensitization can result from a therapeutic 
increase in DNA DSBs or inhibition of their repair.  
Ataxia-telangiectasia-mutated (ATM) protein is an 
important signal transducer of the DNA damage 
response,  which contains DNA repair and cell-cycle 
checkpoints,  and activation of ATM by autophospho-
rylation occurs in response to exposed DNA DSBs 
[62].  Cells with ATM gene mutations have defects in 
cell-cycle checkpoints and DNA repair and are hyper-
sensitive to DSBs [63,  64]; thus,  agents that inhibit 
the ATM pathway can be useful radiosensitizers [65].  
The MRN complex,  consisting of Mre11,  Rad50 and 
NBS1,  is quickly stimulated by DSBs and directly 
activates ATM [66,  67] (Fig.  3).  Defects in the 
MRN complex lead to genomic instability,  telomere 
shortening and hypersensitivity to DNA damage [68].
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Telomelysin Sensitizes Human Cancer Cells to 
Ionizing Radiation
　 Virus infection and replication produce exogenous 
viral proteins,  many of which manipulate the host 
cellular machinery to allow viral persistence in the 
life-cycle.  The adenovirus E1B gene encodes a 
19-kDa polypeptide (E1B19kDa) and a 55-kDa protein 
(E1B55kDa).  These gene products are expressed 
early in viral infection and promote the cytoplasmic 
accumulation of late viral mRNA,  leading to a shutoﬀ 
of host cell protein synthesis.  The E1B55kDa protein 
induces a cellular environment conducive to viral 
protein synthesis via a complex with the E4orf6 pro-
tein [69].  This E1B55kDa/E4orf6 complex degrades 
the MRN complex,  blocks downstream ATM signaling,  
and leads to a defective G2/M checkpoint in response 
to DSBs [67].  Although the impact of E1B55kDa-
mediated disruption of the MRN-ATM pathway on the 
DNA damage responses triggered by ionizing radiation 
has not yet been studied,  we demonstrated that 
Telomelysin-mediated E1B55kDa expression induced 
the degradation of all components of the MRN com-
plex,  which in turn prevented ATM autophosphoryla-
tion following ionizing radiation [70] (Fig. 3).  
Telomelysin expresses the E1B gene under the control 
of the hTERT promoter through an internal ribosome 
entry site sequence,  whereas dl1520 (Onyx-015,  
CI-1042),  which has been used in many clinical trials,  
was genetically modiﬁed by disruption of the coding 
sequence of the E1B55kDa protein [13].  Therefore,  
ionizing radiation-induced ATM activation was blocked 
more eﬃciently by Telomelysin than by dl1520,  which 
lacks E1B55kDa,  although dl1520 slightly inhibited 
ATM phosphorylation,  presumably due to E4orf6 
protein expression [71].
　 Our in vitro studies suggest that Telomelysin infec-
tion and ionizing radiation may mutually sensitize 
human tumor cells,  potentially leading to an eﬀective 
combination treatment.  Telomelysin infection requires 
157Oncolytic Virotherapy for Gastrointestinal CancerJune 2011
DNA double 
strand breaks
MRN complex 
formation
Phospholyration
of ATM
DNA repair
DNA Repair Mechanism after Radiation
NBS1
Mre11 Rad50
ATM
P
✓Cell cycle checkpoint
✓Activation of DNA repair
Radiation
Telomelysin Blocks the Repair of DNA Damages
ATM
P
NBS1
Mre11 Rad50
E1B55k
Telomelysin
infection 
E1B55k binds to 
MRN complex
Activation of MRN 
degradation
Blockade of ATM 
phospholyration
DNA repair 
blockade ✓Cell cycle checkpoint
✓Activation of DNA repair
Radiosensitization
Fig. 3　 Molecular mechanism of Telomelysin-induced radiosensitization.  The MRN complex plays a role as an upstream sensor in 
response to DSBs.  Degradation of the MRN complex by the E1B55K protein prevents ATM autophosphorylation and signaling,  leading to 
the inhibition of the ATM-dependent G2/M checkpoint.
a period of replication to induce the cytopathic eﬀect 
and to sensitize cells to radiation,  whereas ionizing 
radiation immediately causes DNA DSBs.  Therefore,  
in a true clinical setting,  multiple cycles of the 
external-beam radiotherapy followed by intratumoral 
injection of Telomelysin may yield optimal results.  We 
conﬁrmed the synergistic antitumor eﬀect of three 
cycles of treatment with Telomelysin plus regional 
radiation and the in vivo induction of apoptotic cell 
death on subcutaneous human tumor xenografts.  The 
orthotopic implantation of tumor cells,  however,  
restores the correct tumor-host interactions,  which do 
not occur when tumors are implanted in ectopic subcu-
taneous sites [72].  Thus,  we also demonstrated the 
signiﬁcant synergy of combined treatments in an 
orthotopic mouse model of human esophageal cancer by 
using a noninvasive whole-body imaging system.
Clinical Application of Telomelysin
　 Preclinical models suggested that Telomelysin 
could selectively kill a variety of human cancer cells in 
vitro and in vivo via intracellular viral replication regu-
lated by hTERT transcriptional activity.  Pharmaco-
logical and toxicological studies in mice and cotton rats 
demonstrated that none of the animals treated with 
Telomelysin showed signs of viral distress (e.g.,  ruf-
ﬂed fur,  weight loss,  lethargy,  or agitation) or histo-
pathological changes in any organs at autopsy.  These 
promising data led us to design a phase I clinical trial 
of Telomelysin as a monotherapy.
　 The protocol “A phase I study of intratumoral 
injection with telomerase-speciﬁc replication-compe-
tent oncolytic adenovirus,  Telomelysin (OBP-301) for 
various solid tumors,” sponsored by Oncolys 
BioPharma,  Inc.  (Minato-ku,  Tokyo,  Japan),  is an 
open-label,  phase I,  3-cohort dose-escalation study 
[73,  74].  The trial commenced following approval of 
the US Food and Drug Administration (FDA) in 
October,  2006.  The study to assess the safety,  tol-
erability,  and feasibility of intratumoral injection of 
the agent in patients with advanced solid cancer has 
been completed.  The doses of Telomelysin were esca-
lated from low to high virus particles (VP) in one-log 
increments.  Sixteen patients with a variety of solid 
tumors such as melanoma,  head and neck cancer,  
breast cancer,  lung cancer,  and sarcomas were 
treated with a single-dose intratumoral injection of 
Telomelysin and then monitored over one month.
　 All patients received Telomelysin without dose-
limiting toxicity.  Common grade 1 and 2 toxicities 
included injection site reactions (pain,  induration) and 
systemic reactions (fever,  chills).  The data obtained 
on the pharmacokinetics and biodistribution of 
Telomelysin may be of interest.  Clinical trials of 
intratumoral and intravenous administration of 
CG7870,  a replication-selective oncolytic adenovirus 
genetically engineered to replicate preferentially in 
prostate tissue,  demonstrated a second peak of the 
virus genome in the plasma [75,  76],  suggesting 
active viral replication and shedding into the blood-
stream.  In fact,  circulating viral DNA was tran-
siently (＜6h after injection) detected in plasma in 13 
of 16 patients within 24h after injection.  This dose-
dependent initial peak in circulating virus was followed 
by a rapid decline; however,  three patients demon-
strated evidence of prolonged viral replication through 
detection of plasma viral DNA at days 7 and 14,  sug-
gesting Telomelysin replication in primary tumors.  
One of these 3 had disappearance of the injected 
malignant lesion and loco-regional uninjected satellite 
nodules,  fulﬁlling a deﬁnition of complete response at 
day 28.  Seven patients fulﬁlled the RECIST deﬁni-
tion for stable disease by day 56 after treatment,  
while 6 patients showed 6.6 to 43ｵ tumor size reduc-
tion.  Thus,  Telomelysin appears well-tolerated and 
warrants further clinical studies for solid cancer.
Perspectives
　 There have been very impressive advances in our 
understanding of the molecular aspects of human gas-
trointestinal cancer and in the development of tech-
nologies for genetic modiﬁcation of viral genomes.  
Transcriptional targeting is a powerful tool for tumor 
selectivity in cancer therapy,  and the hTERT-speciﬁc 
oncolytic adenovirus achieves a more strict targeting 
potential due to the ampliﬁed eﬀect by viral replica-
tion.  Several independent studies using diﬀerent 
regions of the hTERT promoter and diﬀerent sites of 
the adenoviral genome responsible for viral replication 
have shown that the hTERT promoter allows adenovi-
ral replication as a molecular switch and induces 
selective cytopathic eﬀects in a variety of human 
tumor cells [31-33,  39-41].  Among these viral con-
structs,  to the best of our knowledge,  Telomelysin 
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seems to be the ﬁrst hTERT-dependent oncolytic 
adenovirus that has been used in a clinical trial based 
on preclinical pharmacological and toxicological stud-
ies.  Thus,  this telomerase-speciﬁc targeted oncolytic 
adenovirus holds promise for the treatment of human 
cancer.
　 It has been shown that Telomelysin delivered to the 
primary tumor site could spread into the regional 
draining lymphatic vessels,  selectively replicate in 
neoplastic foci,  and then reduce the number of tumor 
cells in metastatic lymph nodes in an orthotopic human 
colorectal cancer xenograft model [54].  This virus-
mediated molecular surgery for lymph node metastasis 
mimics the clinical scenario of lymphadenectomy; the 
technique,  however,  seems to be safer and less inva-
sive.  Moreover,  we demonstrated that preoperative 
delivery of Telomelysin into primary tumors prevented 
the exacerbation of lymph node metastasis by surgical 
procedures.  Telomelysin may oﬀer advantages over 
other oncolytic viruses targeting lymphatic metastasis,  
as its safety proﬁle as well as biodistribution pattern 
after intratumoral delivery have already been con-
ﬁrmed in a phase I clinical trial for various types of 
solid tumors [73,  74].  Our study provides evidence 
for the in vivo purging eﬀect of Telomelysin in 
regional lymph nodes that is suﬃciently reliable to 
support this approach.
　 A possible future direction for Telomelysin 
includes combination therapy with conventional thera-
pies such as chemotherapy,  radiotherapy,  surgery,  
immunotherapy,  and new modalities such as antiangio-
genic therapy.  Since the results of a phase I clinical 
trial demonstrated that even partial elimination of the 
tumor induced by intratumoral injection of 
Telomelysin could be clinically beneﬁcial,  combination 
approaches may lead to the development of more 
advanced biological therapy for human cancer.  The 
combination of systemic chemotherapy and local injec-
tion of Telomelysin has been previously shown to be 
eﬀective [77-79].  As a replication-deﬁcient adenovi-
rus could replicate in cancer cells and enhance the 
anticancer eﬀect when co-transfected with Telomelysin,  
which can produce the E1 protein,  we demonstrated 
the synergistic eﬀects of Telomelysin combined with 
an E1-deleted replication-deﬁcient adenoviral vector 
expressing the human wild-type p53 tumor suppressor 
gene (Ad5CMV-p53,  Advexin) [80,  81].  As described 
above,  Telomelysin is also synergistic with ionizing 
radiation against human esophageal cancer cells,  and 
we clariﬁed the E1B55kDa-mediated mechanism used 
by Telomelysin to inhibit DNA repair.  Peri- or post-
operative administration of Telomelysin may also be 
valuable as an adjuvant therapy in areas of micro-
scopic residual disease at tumor margins to prevent 
recurrence or regrowth of tumors.
　 The ﬁeld of targeted oncolytic virotherapy is pro-
gressing considerably and is rapidly gaining medical 
and scientiﬁc acceptance.  Although many technical and 
conceptual problems await solutions,  ongoing and 
future clinical studies will no doubt continue to pro-
vide important clues that may allow substantial prog-
ress in human gastrointestinal cancer therapy.  Thus,  
phase II studies of telomerase-speciﬁc virotherapy in 
human cancer patients are warranted.
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